

- Kataoka H, Horita T, Yasuda S, Koike T. The effects of phosphatidylserine dependent antiprothrombin antibody on thrombin generation. *Arthritis Rheum* 60, 2457-67, 2009
10. Nakagawa H, Yasuda S, Matsuura E, Kobayashi K, Ieko M, Kataoka H, Horita T, Atsumi T, Koike T. Nicked beta2-glycoprotein I binds angio- statin4.5 (plasminogen kringle 1-5) and attenuates its anti-angiogenic property. *Blood* 114, 2553-9, 2009.
11. Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, Okamoto A, Yamada R, Myouzen K, Suzuki A, Kubo M, Atsumi T, Koike T, Takasaki Y, Momohara S, Yamanaka H, Nakamura Y, Yamamoto K. The association of a non-synonymous SNP in the TNFAIP3 gene with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. *Arthritis Rheum* (in press)
12. Fukae J, Kon Y, Henmi M, Sakamoto F, Narita A, Shimizu M, Tanimura K, Matsuhashi M, Kamishima T, Atsumi T, Koike T. Change of Synovial Vascularity in Single Finger Joint assessed by Power Doppler sonography correlated with radiographic change in Rheumatoid Arthritis. *Arthritis Rheum* (in press)
13. Kamishima T, Fujieda Y, Atsumi T, Mimura R, Koike T, Terae S, Shirato H. Contrast-Enhanced Whole Body Joint MR Imaging in Patients with Unclassified Arthritis Developing Early Rheumatoid Arthritis in 2 Years: Feasibility Study and Correlation with MR Imaging Findings of the Hands. *Am. J Roentgenol* (in press)
- H. 知的財産権の出願・登録状況 (予定を含む)
1. 特許取得  
該当なし
  2. 実用新案登録  
該当なし
  3. その他  
該当なし

#### IV. 研究成果の刊行に関する一覧表

## 研究成果の刊行に関する一覧表

(竹内 勤)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda JI, Tomita Y, Nakatsuka SI, Tamaru JI, Iizuka A, <u>Takeuchi T</u> , Aozasa K	Lymphoproliferative disorders in Rheumatoid Arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication.	J Rheum	34	322-331	2007
Kameda H, Okuyama A, Tamaru J, Itoyama S, Iizuka A, <u>Takeuchi T</u>	Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate in a patient with rheumatoid arthritis.	Clin Rheum	26	1585-9	2007
Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saitao K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, <u>Takeuchi T</u>	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in rheumatoid arthritis management group in Japan (RECONFIRM)	Mod Rheum	17	28-32	2007
Nagasawa H, Kameda H, Amano K, <u>Takeuchi T</u>	MMP-3.	APLAR J Rheum	10	299-295	2007
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, <u>Takeuchi T</u> , Murata Murata N, van der Heijde D, Kishimoto T	The SAMURAI Study: Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab.	Ann Rheum Dis	66	1162-7	2007
<u>Takeuchi T</u> , Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Harigai Y, Ryu J, Inoue K, Kondo H, Inokuma S, Kamatani N, Ochi T, Koike T	Post-marketing Surveillance of the Safety Profile of Infliximab in 5,000 Japanese Patients with Rheumatoid Arthritis.	Ann Rheum Dis	67	189-94	2008
Kameda H, <u>Takeuchi T</u> .	Platelet-Derived Growth Factor as a Therapeutic Target for systemic autoimmune diseases.	Drug Target Insight	2	1-9	2007

Koike R, <u>Takeuchi T</u> , Eguchi K, Miyasaka N	Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.	Mod Rheum	17	451-458	2007
<u>Takeuchi T</u> , Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Harigai Y, Ryu J, Inoue K, Kondo H, Inokuma S, Kamatani N, Ochi T, Koike T	Post-marketing Surveillance of the Safety Profile of Infliximab in 5,000 Japanese Patients with Rheumatoid Arthritis.	Ann Rheum Dis	67	189-94	2008
Sekiguchi N, Kawauchi S, Furuya T, Matsuda K, Ando S, Ogasawara M, Inaba N, Abe T, Ito S, <u>Takeuchi T</u>	Monitoring of cDNA microarray profile in peripheral blood during infliximab treatment of Rheumatoid Arthritis patients.	Rheumatology	47	780-88	2008
Tanaka Y, <u>Takeuchi T</u> , Inoue E, Saito K, Sekiguchi N, Iikuni N, Nawata M, Kameda H, Shinozaki M, Iwata S, Amano K, Yamanaka H	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II).	Mod Rheum	18	146-52	2008
Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, Hirakata M, Yamada T, Kamatani N, Kikuchi Y, Sugii S, <u>Takeuchi T</u> , Tateda K, Goto H	Clinical radiological features of pneumocystis pneumonia in patients with Rheumatoid Arthritis, in comparison with Methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: A multicenter study	Intern Med	47	915-23	2008
Inokuma S, Sato T, Sagawa A, Matsuda T, Takemura T, Ohtsuka T, Saeki Y, <u>Takeuchi T</u> , Sawada T	Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis.	Mod Rheum	18	442-6	2008
<u>Takeuchi T</u> , Yamanaka H, Inoue E, Nagasawa Y, Nawata M, Ikari K, Saito K, Sekiguchi N, Saito E, Kameda H, Iwata S, Mochizuki T, Amano K, Tanaka Y	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year outcome of joint destruction (RECONFIRM-2J).	Mod Rheum	18	447-52	2008

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, <u>Takeuchi T</u> , Azuma J, Kishimoto T	Study of Active controlled Tocilizumab monotherapy for Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate (SATORI) : significantly reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.	Mod Rheum	19	12-19	2009
Suzuki K, Kameda H, Kondo K, Tanaka Y, <u>Takeuchi T</u>	Two cases of acute exacerbation of lupus manifestation after re-treatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus.	Rheumatology	48	198-99	2009
Suzuki K, Kameda H, Amano K, Nagasawa H, Sekiguchi H, Nishi E, Ogawa H, Tsuzaka K, <u>Takeuchi T</u>	Single Center Prospective Study for Efficacy and Safety of Tacrolimus in Rheumatoid Arthritis.	Rheumatology Int	29	431-6	2009
Nagasawa H, Kameda H, Sekiguchi N, Amano K, <u>Takeuchi T</u>	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction.	Mod Rheum	19	166-172	2009
Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Tanaka Y, <u>Takeuchi T</u> , Miyasaka N	Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.	Arthritis & Rheum	61	305-12	2009
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, <u>Takeuchi T</u> , Azuma J	Long-term safety and efficacy of tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.	Ann Rheum Dis	68	1580-84	2009
Sawada T, Inokuma S, Sato T, Ohtsuka T, Saeki Y, <u>Takeuchi T</u> , Matsuda T, Takemura T, Sagawa A	Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis.	Rheumatology	48	1069-72	2009

Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T	The Impact on Radiographic and Clinical Response of Infliximab Therapy Concomitant with Methotrexate in Patients with Rheumatoid Arthritis by the Trough Serum Level in the Dose Escalating Study: the RISING Study.	Mod Rheumatology	19	478-87	2009
Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N	A combination of biochemical markers of cartilages and markers of cartilage and bone turnover, radiographic image and body mass index to predict progression of joint destruction in patients with rheumatoid Arthritis treated with Disease modifying Anti-Rheumatic Drugs.	Mod Rheum	19	273-282	2009
Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, Takeuchi T	Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.	Biochem Biophys Research Comm	387	261-265	2009
Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M	Post-marketing surveillance of the safety and efficacy of etanercept in Japan.	J Rheum	36	898-906	2009
Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Ohtsuka T, Saeki Y, Takeuchi T, Sawada T	Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.	Rheumatology	48	1265-8	2009
Ogawa H, Kameda H, Amano K, Takeuchi T	Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.	Lupus	19	162-169	2010
Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H, Honda N, Yasaki Y, Itoyama S, Tszaka K, Takeuchi T	IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialoadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation.	Rheumatology (in press)			

Suzuki K, Kameda H, Amano K, Nagasawa H, Takeii H, Nishi E, Okuyama A, Tsuzaka K, Takeuchi T	Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus.	Rheumatology Int	29	431-6	2009
Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T	Normalization of physical function by infliximab in RA patients: Factors associated with normal physical function.	Clin Exp Rheum (in press)			
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study.	Ann Rheum Dis (in press)			
Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis.	Mod Rheum (in press)			
Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T, Japan Biological Agent Integrated Consortium (J-BASIC)	The comparison of efficacy and safety between continuation and discontinuation of methotrexate (MTX) at the commencement of etanercept in patients with active rheumatoid arthritis despite MTX therapy: 24-week results from the JESMR study.	Rheumatology (in press)			

(山本 一彦)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kochi Y, Suzuki A, Yamada R, <u>Yamamoto K</u>	Genetics of rheumatoid arthritis: underlying evidence of ethnic differences.	J Autoimmun.	32	158-62	2009
Okada Y, Yamada R, Suzuki A, Kochi Y, Shimane K, Myouzen K, Kubo M, Nakamura Y, <u>Yamamoto K</u>	Contribution of a haplotype in the HLA region to anti-cyclic citrullinated peptide antibody positivity in rheumatoid arthritis, independently of HLA-DRB1	Arthritis Rheum.	60	3582-90	2009

Kobayashi S, Ikari K, Kaneko H, Kochi Y, <u>Yamamoto K</u> , Shimane K, Nakamura Y, Toyama Y, Mochizuki T, Tsukahara S, Kawaguchi Y, Terai C, Hara M, Tomatsu T, Yamanaka H, Horiuchi T, Tao K, Yasutomo K, Hamada D, Yasui N, Inoue H, Itakura M, Okamoto H, Kamatani N, Momohara S.	Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population.	Arthritis Rheum.	58	1940-6	2008
Suzuki A, Yamada R, Kochi Y, Sawada T, Okada Y, Matsuda K, Kamatani Y, Mori M, Shimane K, Takahashi A, Tsunoda T, Miyatake A, Kubo M, Kamatani N, Nakamura Y, <u>Yamamoto K</u>	Functional SNPs in CD244 gene increase the risk of rheumatoid arthritis in a Japanese population.	Nat Genet.	40	1224-9	2008
Okada Y, Mori M, Yamada R, Suzuki A, Kobayashi K, Kubo M, Nakamura Y, <u>Yamamoto K</u>	SLC22A4 polymorphism and rheumatoid arthritis susceptibility: a replication study in a Japanese population and a metaanalysis.	J Rheumatol.	35	1723-8	2008
Suzuki A, Yamada R, <u>Yamamoto K</u>	Citrullination by peptidylarginine deiminase in rheumatoid arthritis	Ann NY Acad Sci.	1108	323-39	2007
<u>Yamamoto K</u> , Yamada R	Lessons from a Genomewide Association Study of Rheumatoid Arthritis	N.Engl.J.Med.	357	1250-51	2007
Yamada R, <u>Yamamoto K</u>	Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.	Nat Clin Pract Rheumatol	3	644-50	2007



(西本 憲弘)

[書籍]

発表者氏名	論文タイトル名	書籍全体の編集者名 書籍名	出版社名 出版地	出版年 ページ
<u>Nishimoto N</u> , Kishimoto T	Update on interleukin-6 In: Smolen J, Lipsky P, eds. Contemporary Targeted	Smolen J, Lipsky P	martin Dunitz	2007
		Therapies in Rheumatology	London	149-158
<u>Nishimoto N</u> , Kishimoto T	Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab.In	Chernajovsky Y, Nissim A	Sp r inger-verlag	2008
		eds. Therapeutic Antibodies. Handbook of Experimental Pharmacology.	Berlin Heiderberg	151-160
<u>Nishimoto N</u> , Mima T	Tocilizumab In	Hochberg M, Weinblatt M, Weisman M, Smolen J and Silman A	Elsevier	2008
		eds Rheumatoid Arthritis		367-371
Mima T, <u>Nishimoto N</u> .	Clinical value of blocking IL-6 receptor			2009
		Current Opimion in Rheumatology		224-230

[雑誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
西本憲弘	トシリズマブ (ヒト化モノクローナル抗ヒト IL-6 受容体抗体) の有用性	治療	89	367-371	2007
西本憲弘	トシリズマブの有効性と炎症制御における利点—関節リウマチにおける IL-6 阻害治療の利点	医学のあゆみ	221	432-436	2007
西本憲弘	抗 IL-6 受容体抗体の関節リウマチに対する治療効果	CLINICAL CALCIUM	17	126 (562) -132(568)	2007
西本憲弘	特集 I 新しい生物学的製剤 抗 IL-6 受容体抗体トシリズマブ	炎症と免疫	15	9(553) -13(557)	2007
西本憲弘	次世代の IL-6 ブロッカー：トシリズマブ	Mebio	24	76-83	2007
<u>Nishimoto N</u> , Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T	Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab	Ann Rheum D	66	1162-1167	2007

吉雄直子, 西本憲弘	生物学的製剤の使い分け	臨床リウマチ	20	13-18	2008
西本憲弘	日本発のエビデンスをどう読むか? SAMURAI 研究	分子リウマチ治療	1	9(59) -13(63)	2008
西本憲弘, 吉雄直子	関節リウマチに対する IL-6 阻害療法の実際	Medical Practice	25	1391-1396	2008
西本憲弘	RA の骨破壊における IL-6 の役割とトシリズマブによる骨破壊抑制効果	リウマチ科	40	120-125	2008
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T	Mechanisms and pathological significances in serum interleukin-6(IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody,tocilizumab,in patients with rheumatoid arthritis and Castleman's disease	Blood	112	3959-3964	2008
西本憲弘	IL-6 標的治療の関節破壊抑制効果	CLINICAL CALCIUM	19	33-139	2009
西本憲弘	IL-6 阻害療法診療ガイドライン	臨床雑誌「内科」	4	669-673	2009
西本憲弘	骨代謝・関節破壊抑制における抗 IL-6 受容体抗体の効果はどのような	分子リウマチ治療	2	165-169	2009
中原英子, 西本憲弘	トシリズマブ—わが国のエビデンス (SATORI, SAMURAI, STREAM)	リウマチ科	42	287-294	2009
西本憲弘	トシリズマブは first choice biologics となりうるか? Mebio 特集：関節リウマチ治療—drug free—そして真の寛解を目指して—	メディカルビュー	7	52-61	2009
Ishikawa S, Mima T, Aoki C, Yoshio-Hoshino N, Adachi Y, Imagawa T, Mori M, Tomiita M, Iwata N, Murata T, Miyoshi M, Takei S, Aihara Y, Yokota S, Matsubara K, Nishimoto N.	Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA maicroarray analysis	Ann Rheum Dis	68	264-272	2009

<u>Nishimoto N</u> , Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azumi J., Kishimoto T	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy	Mod Rheumatol	19	14-19	2009
Hashimoto J, Garner P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, <u>Nishimoto N</u> .	A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs	Mod Rheumatol	19	273-282	2009
Lee H, Mima T, Sugino H, Aoki C, Hoshino-N.Y, Matsubara K, <u>Nishimoto N</u>	Interactions among type I and type II interferon, tumor necrosis factor, and $\beta$ -estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus	Arthritis Research & Therapy	11R1	1-10	2009
Fujiwara H, <u>Nishimoto N</u> , Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M	Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: report of two cases	Mod Rheumatol	19	64-68	2009
<u>Nishimoto N</u> , Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azumi J	Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study	Ann Rheum Dis	68	1580-1584	2009
Nishimoto N	Interleukin-6 as a therapeutic target in candidate inflammatory diseases	Clinical Pharmacology & Therapeutics		(in press)	2009
Mima T, <u>Nishimoto N</u>	Clinical value of blocking IL-6 receptor.	Current Opinion in Rheumatology		224-230	2009
西本憲弘	抗 IL-6 受容体抗体 トシリズマブ	最新医学社		84-88	2009

(住田 孝之)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Iwanami K, Matsumoto I, Tanaka Y, Inoue A, Minami R, Hayashi T, Goto D, Ito S, Nishimura Y, <u>Sumida T</u>	Altered peptide ligands inhibit glucose-6-phosphate isomerase (GPI) peptide-induced arthritis.	Arthritis Res. Ther. (in press)			
Ito I, Kawasaki A, Ito S, Kondo S, Sugihara M, Horikoshi M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Takasaki Y, Hashimoto H, Matsuta K, <u>Sumida T</u> , Tsuchiya N,	Replication of association between FAM167A (C8orf13)-BLK region and rheumatoid arthritis in a Japanese population.	Ann. Rheum. Dis. (in press)			
Segawa S, Goto D, Yoshiga Y, Sugihara M, Hayashi T, Chino Y, Matsumoto I, Ito S, <u>Sumida T</u>	Inhibition of TGF- $\beta$ signaling attenuates IL-18 plus IL-2-induced interstitial lung disease.	Clin. Exp. Immunol. (in press)			
Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, Tsutsumi A, Uchida K, Usui J, Yamagata K, <u>Sumida T</u>	Analysis of cytokine balance in lupus nephritis by laser-microdissection.	Clin. Exp. Immunol. (in press)			
Inoue A, Matsumoto I, Tanaka Y, Iwanami K, Goto D, Ito S, <u>Sumida T</u>	Role of tumor necrosis factor- $\alpha$ -induced adipose-related protein in autoimmune arthritis.	Arthritis Res. Ther. (in press)			
Segawa S, Goto D, Yoshiga Y, Hayashi T, Matsumoto I, Ito S, <u>Sumida T</u>	The decrement of soluble CD1d proteins affects the function of NKT cells in patients with rheumatoid arthritis.	Int. J. Mol. Med.	24	481-486	2009
Tanaka-Watanabe Y, Matsumoto I, Iwamami K, Inoue A, Goto D, Ito S, Tsutsumi A, <u>Sumida T</u>	B cells have crucial role as autoantibody producers in arthritis mediated by glucose-6-phosphate isomerase.	Clin. Exp. Immunol.	155	285-294	2009

Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, <u>Sumida T</u> , Tsuchiya, N	Replication of the association between C8orf13-BLK region and systemic lupus erythematosus in a Japanese population.	Arthritis Rheum.	60	553-558	2009
Kawaguchi Y, Wakamatsu E, Matsumoto I, Nishimagi E, Kamatani N, Satoh T, Kuwana M, <u>Sumida T</u> , Hara, M	Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.	Ann. Rheum. Dis.	68	710-714	2009
Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, Hayashi T, Goto D, Matsumoto I, <u>Sumida T</u>	A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.	Mod. Rheumatol.	19	358-365	2009
Iwanami K, Matsumoto I, Tanaka Y, Inoue A, Goto D, Ito S, Tsutsumi A, <u>Sumida T</u>	The dominant arthrogenic T cell epitope in glucose-6-phosphate isomerase (GPI)-induced arthritis.	Arthritis Res. Ther.	10	R130. Epub 2008 Nov 7.	2008
Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham R R, Hom G, Takasaki Y, Hashimoto H, Behrens TW, <u>Sumida T</u> , Tsuchiya, N	Association of STAT4 polymorphisms with systemic lupus erythematosus in a Japanese population.	Arthritis Res. Ther.	10	R113. Epub 2008 Sep 19.	2008
Matsumoto I, Zhang H, Yasukochi T, Iwanami K, Tanaka Y, Inoue A, Goto D, Ito S, Tsutsumi A, <u>Sumida T</u>	Therapeutic effects of antibodies to TNF $\alpha$ and IL-6 and CTLA-4 Ig in mice with glucose-6-phosphate isomerase-induced arthritis.	Arthritis Res. Ther.	10	R66.Epub 2008 Jun 5.	2008
Iwanami K, Matsumoto I, Watanabe Y, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, <u>Sumida T</u>	Crucial role of IL-6/IL-17 cytokine axis in the induction of arthritis by glucose-6-phosphate-isomerase.	Arthritis Rheum.	58	754-763	2008

Nakamura Y, Wakamatsu E, Tomiita M, Kohno Y, Yokoka J, Goto D, Ito S, Matsumoto I, Tsutsumi A, <u>Sumida, T</u>	High prevalence of autoantibodies to muscarinic 3 acetylcholine receptor in patients with juvenile Sjögren's syndrome.	Ann. Rheum. Dis.	67	136-137	2008
Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S, Tsutsumi A, Taniguchi M, <u>Sumida, T</u>	NKT cells are novel accelerator of IL-17 in the pathogenesis of collagen-induced arthritis.	Int. J. Mol. Med.	22	369-374	2008
Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K, Kohno M, Goto D, Matsumoto I, Ito S, <u>Sumida, T</u>	Expression of Visfatin (pre-B cell colony-enhancing factor) gene in patients with rheumatoid arthritis.	Ann. Rheum. Dis.	67	571-572	2008
Sugihara M, Tsutsumi A, Suzuki E, Suzuki T, Ogishima H, Hayashi T, Chino Y, Ishii W, Manura M, Goto D, Matsumoto I, Ito S, <u>Sumida T</u>	The gene expressions of TNF $\alpha$ , TTP, TIA-1 and HuR in the peripheral blood mononuclear cells of patients with rheumatoid arthritis before and after infliximab therapy.	Arthritis Rheum.	56	2160-2169	2007
Wakamatsu E, Nakamura Y, Matsumoto I, Goto D, Ito S, Tsutsumi A, <u>Sumida T</u>	DNA microarray analysis of labial salivary glands from patients with Sjogren's syndrome.	Ann. Rheum. Dis.	66	844-845	2007

(田中 良哉)

[書 籍]

発表者氏名	論文タイトル名	書籍全体の編集者名 書籍名	出版社名 出版地	出版年 ページ
田中良哉	自己免疫疾患の医療ニーズ.	山脇良平	技術情報協会	2008
		抗体医薬品の研究開発 ノウハウ集 2008.	東京	34-41
田中良哉	関節リウマチ	山口昭生	岩波書店	2009
		40歳からの女性の医学 関節リ ウマチ 新しい治療、正しい知識 で克服する	東京	1-123
田中良哉	全身エリテマトーデス	山口 徹、北原光夫、福井次矢	医学書院	2009
		今日の治療方針 2009年版 ー私はこう治療している	東京	608-610
田中良哉	生物学的製剤 ～抗サイトカイン療法を中心 に～	松島鋼次、西脇 徹	朝倉書店	2009
		炎症・再生医学辞典	東京	344-347
田中良哉	膠原病・リウマチ性疾患の薬 物治療免疫抑制薬、抗リウマ チ薬、生物学的製剤	小川聰	中山書店	2009
		内科学書	東京	151-154

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakayamada S, Saito K, Nakano K, <u>Tanaka Y</u>	$\beta$ 1 integrin transduces an activation signal in T cells of patients with systemic lupus erythematosus.	Arthritis Rheum	56	1559-1568	2007
Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, <u>Tanaka Y</u>	Leflunomid inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.	J Immunol	179	6479-6484	2007
Tsujimura S, Saito K, Nakayamada S, <u>Tanaka Y</u>	Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus.	Histol Histopathol	22	465-468	2007

Tsujimura S, Saito K, Nawata M, Nakayamada S, <u>Tanaka Y</u>	Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.	Ann Rheum Dis	in press		
Takeuchi T, Tatsuki T, Nogami N, Ishiguro N, <u>Tanaka Y</u> , Yamanaka H, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Kamatani N, Ochi T, Koike T	Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis.	Ann Rheum Dis	67	189-195	2008
Tsujimura S, Saito K, Nawata M, Nakayamada S, <u>Tanaka Y</u>	Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.	Ann Rheum Dis	67	380-388	2008
Nishida K, Okada Y, Nawata M, Saito K, <u>Tanaka Y</u>	Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody.	Endocrine J	55	213-216	2008
Tanikawa R, Okada Y, Nakano K, Tanikawa T, Hirashima M, Yamauchi A, Hosokawa R, <u>Tanaka Y</u>	Interaction of galectin-9 with lipid rafts induces osteoblast proliferation through the c-Src/ERK signaling pathway.	J Bone Miner Res	23	278-286	2008
<u>Tanaka Y</u> , Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H.	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2)	Mod Rheumatol	18	146-152	2008
Tsujimura S, Saito K, Nakayamada S, <u>Tanaka Y</u>	Bolus infusion of human urinary trypsin inhibitor improves intractable interstitial pneumonia in patients with connective tissue diseases.	Rheumatology	47	907-913	2008
Nakano K, Higashi T, Hashimoto K, Takagi R, <u>Tanaka Y</u> , Matsushida S.	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis.	Biochem Biophys Res Commun	373	286-291	2008



Mototani H, Iida A, Nakajima M, Furuichi T, Miyamoto Y, Tsunoda T, Sudo A, Kotani A, Uchida A, Ozaki K, <u>Tanaka Y</u> , Nakamura Y, Tanaka T, Notoya K, Ikegawa S.	A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese.	Hum Mol Genet	17	1790-1797	2008
Yoda A, Toyoshima K, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, <u>Tanaka Y</u> , Minami Y.	Arsenic trioxide augments chk2/p53-mediated apoptosis by inhibiting oncogene wip1 phosphatase.	J Biol Chem	283	18969-18979	2008
Takizawa Y, Inokuma S, Tanaka Y, Saito K, Atsumi T, Hirakata M, Kameda H, Hirohata S, Kondo H, Kumagai S, <u>Tanaka Y</u>	Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population.	Rheumatology	47	1373-1378	2008
Nawata M, Saito K, Nakayamada S, <u>Tanaka Y</u>	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.	Mod Rheumatol	18	460-464	2008
Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, Saito K, Sekiguchi N, Sato E, Kameda H, Iwata S, Mochizuki T, Amano K, <u>Tanaka Y</u>	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).	Mod Rheumatol	18	447-454	2008
Okada Y, Nawata M, Nakayamada S, Saito K, <u>Tanaka Y</u>	Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.	J Rheumatol	35	2249-2254	2008
Komano Y, Harigai H, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, <u>Tanaka Y</u> , Takeuchi T, Miyasaka N.	Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.	Arthritis Care Research	in press		

Koike T, Harigai M, Inokuma S, Inoue, Ishiguro N, Ryu J, Takeuchi T, <u>Tanaka Y</u> , Yamanaka H, Fujii K, Freundlich B, Suzukawa M.	Post-marketing surveillance of the safety and effectiveness of etanercept in Japan	J Rheumatol	in press		
Suzuki K, Nakawaga H, Kameda H, Amano K, Kondo T, Itoyama S, <u>Tanaka Y</u> , Takeuchi T.	Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus.	Rheumatology	48	198-199	2009
Komano Y, Harigai H, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, <u>Tanaka Y</u> , Takeuchi T, Miyasaka N.	Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.	Arthritis Care Research	61	305-312	2009
Matsuura A, Tsukada J, Mizobe T, Higashi T, Mouri F, Tanikawa R, Yamauchi A, Hirashima M, <u>Tanaka Y</u> .	Intracellular galectin-9 activates inflammatory cytokines in monocytes.	Genes Cells	14	511-521	2009
Koike T, Harigai M, Inokuma S, Inoue, Ishiguro N, Ryu J, Takeuchi T, <u>Tanaka Y</u> , Yamanaka H, Fujii K, Freundlich B, Suzukawa M.	Post-marketing surveillance of the safety and effectiveness of etanercept in Japan	J Rheumatol	36	898-906	2009
Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Hanami K, <u>Tanaka Y</u>	Effects of anti-TNF- $\alpha$ antibody infliximab in refractory entero-Beçet's disease.	Rheumatology	48	1012-1013	2009
Nakano K, Higashi T, Takagi R, Hashimoto K, <u>Tanaka Y</u> , Matsushita S.	Dopamine released by dendritic cells polarizes Th2 differentiation.	Int Immunol	21	645-654	2009

Tanikawa T, Okada Y, Tanikawa R, <u>Tanaka Y</u>	Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.	J Vascular Res	46	572-580	2009
Nakayamada S, Fujimoto T, Nonomura A, Saito K, Nakamura S, <u>Tanaka Y</u>	Usefulness of initial histological features for stratifying Sjögren's syndrome	Rheumatology	48	1279-1282	2009
Hirose A, Tanikawa T, Mori H, Okada Y, <u>Tanaka Y</u>	Advanced glycation end products increase endothelial permeability through RAGE/Rho signaling pathway.	FEBS Lett	584	61-66	2009
Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, <u>Tanaka Y</u>	A calcineurin inhibitor, tacrolimus overcomes treatment-unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.	J Rheumatol	in press		
Tsujimura S, Saito K, Nakayamada S, <u>Tanaka Y</u>	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis.	Mod Rheumatol	in press		
Ikenouchi-Sugita A, Yoshimura R, Kishi T, Umene-Nakano W, Katsuki A, Saito K, Iwata H, <u>Tanaka Y</u> , Nakamura J.	No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients.	World J Biol Psychiatry	in press		
Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, <u>Tanaka Y</u>	Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling.	Arthritis Rheum	in press		
<u>Tanaka Y</u> , Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T.	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study.	Ann Rheum Dis	in press		
Choo Q-Y, Ho PC, <u>Tanaka Y</u> , Lin H-S.	Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.	Rheumatology	in press		

(山中 寿)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A, Hara M, Momohara S, Kamatani N, <u>Yamanaka H</u>	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.	Mod Rheumatol.	Epub ahead of print		2010
Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, Shimane K, Nakamura Y, Yano K, Iikuni N, Tsukahara S, Kamatani N, Okamoto H, Kaneko H, Kawaguchi Y, Hara M, Toyama Y, Horiuchi T, Tao K, Yasutomo K, Hamada D, Yasui N, Inoue H, Itakura M, <u>Yamanaka H</u> , Momohara S	Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.	Ann Rheum Dis.	69(2)	368-373	2009
Urano W, Furuya T, Inoue E, Taniguchi A, Urano T, Kotake S, Sekita C, Inoue S, Hara M, Momohara S, Kamatani N, <u>Yamanaka H</u>	Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients.	J Bone Miner Metab.	27(5)	574-583	2009
Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, Tomatsu T, Kamatani N, <u>Yamanaka H</u>	The influence of sex on patients with rheumatoid arthritis in a large observational cohort.	J Rheumatol.	36(3)	508-511	2009
Momohara S, Ikari K, Mochizuki T, Kawamura K, Tsukahara S, Toki H, Hara M, Kamatani N, <u>Yamanaka H</u> , Tomatsu T	Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan.	Ann Rheum Dis.	68(2)	291-292	2009
Furuya T, Urano T, Ikari K, Kotake S, Inoue S, Hara M, Momohara S, Kamatani N, <u>Yamanaka H</u>	A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis.	Mod Rheumatol.	19(2)	140-146	2009